quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:55:57·44d
SECFiling
BioNTech SE logo

SEC Form 20-F filed by BioNTech SE

BNTX· BioNTech SE
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • BNTX
    BioNTech SE
    Health Care

Recent analyst ratings

  • Feb 2UpdateLeerink Partners$113.00
  • Jan 16UpdateGoldman$142.00
  • Jun 5UpdateH.C. Wainwright$145.00
  • May 29UpdateGoldman$110.00
  • Mar 13UpdateCitigroup$145.00
  • Jan 10UpdateTruist$172.00

Related

  • INSIDER14h
    Chief Operating Officer Poetting Sierk sold $5,527,960 worth of Ordinary Shares (50,000 units at $110.56) (SEC Form 4)
  • PR2d
    BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
  • INSIDER10d
    Amendment: SEC Form 3 filed by new insider Sahin Ugur
  • SEC10d
    SEC Form 6-K filed by BioNTech SE
  • PR12d
    BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
  • SEC21d
    SEC Form 6-K filed by BioNTech SE
  • SEC22d
    Amendment: SEC Form 20-F/A filed by BioNTech SE
  • INSIDER29d
    SEC Form 3 filed by new insider Blackwood Nicola Claire
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022